Earnings Call · Q4 FY2022·2023-02-02

Q4 22EPS +5.19%·Rev n/aQ3 22EPS +8.19%·Rev n/aQ2 22EPS +9.36%·Rev n/aQ1 22EPS +16.94%·Rev n/a⚠ consensus missing

Merck & Co., Inc. MRK

Peter Dannenbaum — Investor Relations

Rob Davis — Chairman and Chief Executive Officer

Caroline Litchfield — Chief Financial Officer

Dr. Dean Li — President, Merck Research Laboratories

−3.3%1d on move date−4.7% vs SPY3d−2.8%5d−0.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MRK calls or request research access.

More MRK calls Browse calls Request research access